Multicenter, Prospective, Randomized, Controlled, Double-blind Trial on the Impact of Rosuvastatin on Subclinical Markers of Atherosclerosis in Patients With Primary Necrotizing Vasculitides
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 23 Oct 2019
Price : $35 *
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis
- Focus Therapeutic Use
- 23 Oct 2019 Route and form assumed form RDI.
- 18 Oct 2019 Planned End Date changed from 1 Apr 2020 to 1 Nov 2019.
- 18 Oct 2019 Planned primary completion date changed from 1 Oct 2019 to 1 Nov 2019.